New drug combo shows promise in early trial for advanced melanoma
NCT ID NCT03769155
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing whether adding an experimental drug called VX15/2503 to standard immunotherapies (ipilimumab or nivolumab) can help treat stage IIIB-D melanoma that can be removed by surgery. About 41 participants will receive the drug combination before surgery to see how it affects immune cells in the tumor. The goal is to find better ways to shrink or control the cancer before surgical removal.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
VX15/2503 (pepinemab) combined with ipilimumab or nivolumab
What this could lead to
If successful, this could point toward a more effective treatment approach for advanced melanoma that can be surgically removed.
What could go wrong
This is an early phase 1 trial with only 41 participants, so results are preliminary and may not lead to a standard treatment. Side effects from the drug combination are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PATHOLOGIC STAGE IIIB CUTANEOUS MELANOMA AJCC V8 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia, 30322, United States